Pulmatrix (FRA:2PU) FCF Yield %: -81.74 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2PU Pulmatrix Inc FRA:2PU
32 GF Score
Price €1.21
! 1 Warning Sign
View Full Analysis

What is Pulmatrix FCF Yield %?

Pulmatrix FRA:2PU -8.07% 32 FCF Yield % is -81.74 as of Jul. 16, 2026. GuruFocus rates FRA:2PU with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Pulmatrix ranks worse than 88.43% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Pulmatrix's Trailing 12-Month Free Cash Flow is €-4.04 Mil, and Market Cap is €5.04 Mil. Therefore, Pulmatrix's FCF Yield % for today is -81.74%.

The historical rank and industry rank for Pulmatrix's FCF Yield % or its related term are showing as below:

FRA:2PU' s FCF Yield % Range Over the Past 10 Years
Min: -391.31   Med: -62.58   Max: 28.7
Current: -81.74


During the past 13 years, the highest FCF Yield % of Pulmatrix was 28.70%. The lowest was -391.31%. And the median was -62.58%.

FRA:2PU's FCF Yield % is ranked worse than
88.43% of 1409 companies
in the Biotechnology industry
Industry Median: -9.47 vs FRA:2PU: -81.74

Pulmatrix's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Pulmatrix FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Pulmatrix FCF Yield % Related Terms


Pulmatrix FCF Yield % Historical Data

* Premium members only.

The historical data trend for Pulmatrix's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmatrix FCF Yield % Chart

Pulmatrix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -77.09 -153.76 -246.96 -48.44 -73.27

Pulmatrix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.26 -30.52 -25.75 -38.09 -108.47

FRA:2PU vs CDIO, NXTC, BCAB: FCF Yield % Comparison

For the Biotechnology subindustry, Pulmatrix's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmatrix FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Pulmatrix's FCF Yield % falls into.


FRA:2PU
32GF Score
Pulmatrix Inc FRA:2PU
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmatrix FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Pulmatrix's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-4.64 / 6.332568
=-73.27%

Pulmatrix's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.923 * 4 / 3.403664
=-108.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -81.74 mean?
Pulmatrix (FRA:2PU) has a FCF Yield % of -81.74 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pulmatrix and its competitors. According to the industry distribution chart, Pulmatrix ranks #1246 out of 1409 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Pulmatrix's FCF Yield % too high?
Pulmatrix's current FCF Yield % is -81.74. Based on the distribution chart, Pulmatrix ranks #1246 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pulmatrix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Pulmatrix's FCF Yield % compare to CDIO and NXTC?
According to the Biotechnology industry distribution chart, Pulmatrix ranks #1246 out of 1409 companies for FCF Yield %. This places Pulmatrix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Pulmatrix and its competitors. Pulmatrix's current FCF Yield % is -81.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmatrix stock overvalued right now?
Pulmatrix (FRA:2PU) has a current FCF Yield % of -81.74. The current FCF Yield % is -81.74. Pulmatrix's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Pulmatrix (FRA:2PU), the current FCF Yield % is -81.74 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pulmatrix Business Description

Other Exchanges PULM:USA
Address 945 Concord Street, Suite 1217, Framingham, MA, USA, 01701
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
32GF Score

Get the complete analysis for FRA:2PU

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price